Paradigm Therapeutics Nominated for Prestigious Prix Galien USA 2026 Award for Innovative Therapy
Paradigm Therapeutics Gains Recognition in Biopharmaceutical Field
Paradigm Therapeutics, Inc., a biopharmaceutical company in the clinical development phase, is once again in the spotlight. This time, the company has been nominated for the prestigious Prix Galien USA 2026 award in the “Best Start-up” category, marking a significant milestone as they celebrate a second consecutive nomination. Their innovative therapy, SD-101 (Zorblesia™), is designed to treat the entire skin surface of patients suffering from Epidermolysis Bullosa (EB), a rare genetic condition known for causing fragile skin.
What is the Prix Galien?
The Prix Galien is considered one of the highest honors in the biopharmaceutical industry, often likened to the
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.